Examining immune-related molecules for the discovery of potential therapeutic targets in non-small cell lung cancers through the analysis of fresh peripheral blood and/or pleural effusion from patients treated with anti-PD-1 antibodies. - Immune-profiling of fresh peripheral blood and/or pleural effusion from non-small cell lung cancer patients treated with anti-PD-1 antibodies.

Prospective immune-profiling using fresh whole blood still on going. In follow-up study after discontinuation of anti-PD-1 treatment, we monitored anti PD-1 antibody binding and immune profiling in T cells until complete loss of residual therapeutic antibody binding. We reported the partial results at IASLC meeting 2017(https://www.sciencedirect.com/science/article/pii/S1556086417329428). We completed the recruitment for the follow-up study May 2017.